Filtered By:
Source: Circulation Journal
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 22 results found since Jan 2013.

Statin Adherence After Ischemic Stroke or Transient Ischemic Attack Is Associated With Clinical Outcome.
CONCLUSIONS: Good statin adherence was associated with better clinical outcome in patients with acute ischemic stroke or TIA. PMID: 26742588 [PubMed - as supplied by publisher]
Source: Circulation Journal - January 8, 2016 Category: Cardiology Authors: Chen PS, Cheng CL, Kao Yang YH, Li YH Tags: Circ J Source Type: research

Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy.
CONCLUSIONS: Non-fasting TG could be considered as a substitute for fasting TG as a risk stratification for future CV events among Japanese diabetic patients. PMID: 32023582 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 5, 2020 Category: Cardiology Authors: Tada H, Nomura A, Yoshimura K, Itoh H, Komuro I, Yamagishi M, Takamura M, Kawashiri MA Tags: Circ J Source Type: research

Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction.
Conclusions:On 2-year comparison of hydrophilic and lipophilic statins there was no significant difference in prevention of secondary cardiovascular outcome. PMID: 25392071 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 12, 2014 Category: Cardiology Authors: Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, Sakurai S, Kagoshima M, Tomita T, Miyashita Y, Koyama J, Ikeda U Tags: Circ J Source Type: research

Differential Effects of Strong and Regular Statins on the Clinical Outcome of Patients With Chronic Kidney Disease Following Coronary Stent Implantation.
Conclusions:In patients with mild-to-moderate CKD, only strong statins were associated with lower risk compared with no statin, but regular statins were not. It is possible that taking a strong statin from the early stage of CKD is useful for suppression of cardiovascular events. PMID: 25739954 [PubMed - as supplied by publisher]
Source: Circulation Journal - February 24, 2015 Category: Cardiology Authors: Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kaikita K, Oshima S, Nakao K, Shimomura H, Tsunoda R, Hirose T, Kajiwara I, Matsumura T, Nakamura N, Yamamoto N, Koide S, Oka H, Morikami Y, Sakaino N, Matsui K, Ogawa H, on behalf of the Kumamoto Inter Tags: Circ J Source Type: research

Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
CONCLUSIONS: Main manifestations of ASCVD in FH patients were premature, multivessel CAD with need for recurrent revascularization, associated with classical cardiovascular risk factors but not with peak LDL-C. In spite of intensive therapy with lipid-lowering agents, treatment gaps were significant, with low attainment of LDL-C treatment goals. PMID: 28701632 [PubMed - as supplied by publisher]
Source: Circulation Journal - July 12, 2017 Category: Cardiology Authors: Zafrir B, Jubran A, Lavie G, Halon DA, Flugelman MY, Shapira C Tags: Circ J Source Type: research

Clinical Characteristics and Long-Term Outcomes of Rotational Atherectomy 　- J2T Multicenter Registry.
CONCLUSIONS: This study has provided the largest Japanese dataset for long-term follow-up of RA. Although RA in calcified lesions appears feasible with a high rate of procedural success, a high incidence of MACE was observed. PMID: 28931790 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 21, 2017 Category: Cardiology Authors: Okai I, Dohi T, Okazaki S, Jujo K, Nakashima M, Otsuki H, Tanaka K, Arashi H, Okabe R, Nagura F, Nara Y, Tamura H, Kurata T, Kawashima H, Kyono H, Yamaguchi J, Miyauchi K, Kozuma K, Hagiwara N, Daida H Tags: Circ J Source Type: research

Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels < 70 mg/dL.
CONCLUSIONS: RLP-C levels are a residual risk factor for future CVEs in patients with CAD and on-statin LDL-C <70 mg/dL. PMID: 30996151 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 17, 2019 Category: Cardiology Authors: Fujihara Y, Nakamura T, Horikoshi T, Obata JE, Fujioka D, Watanabe Y, Watanabe K, Kugiyama K Tags: Circ J Source Type: research

Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention 　- A Meta-Analysis of 12 Randomized Trials.
CONCLUSIONS: In secondary prevention patients, the relative benefits of high-dose statin, ezetimibe-statin, and PCSK9 inhibitor-statin treatments were varied and decreased gradually, of which high-dose statin was significantly superior to PCSK9 inhibitor-statin for improving MACE and revascularization per 1 mmol/L reduction of LDL-C. PMID: 31006730 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 18, 2019 Category: Cardiology Authors: Wang S, Xiu J, Liao W, Liao Y, Bin J Tags: Circ J Source Type: research

Lipoprotein(a) and Cardiovascular Diseases 　- Revisited.
Lipoprotein(a) and Cardiovascular Diseases　- Revisited. Circ J. 2020 Apr 24;: Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Abstract Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with cardiovascular disease (CVD). However, the importance of Lp(a) was not strongly established due to a lack of both Lp(a)-lowering therapy and evidence that reducing Lp(a) levels improves CVD risk. Recent advances in clinical and genetic research have revealed the crucial role of Lp(a) in the pathogenesis of CVD. Mendelian randomization studies have shown that ...
Source: Circulation Journal - April 23, 2020 Category: Cardiology Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Tags: Circ J Source Type: research

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects 　- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
CONCLUSIONS: Use of evolocumab robustly lowers LDL-C and is equally efficacious in lowering the risk of cardiovascular events and safe in Asians as it is in others.PMID:33980763 | DOI:10.1253/circj.CJ-20-1051
Source: Circulation Journal - May 13, 2021 Category: Cardiology Authors: Anthony C Keech Kazuma Oyama Peter S Sever Minao Tang Sabina A Murphy Atsushi Hirayama Chen Lu Leslie Tay Prakash C Deedwania Chung-Wah Siu Armando Lira Pineda Donghoon Choi Min-Ji Charng John Amerena Wan Azman Wan Ahmad Vijay K Chopra Terje R Pedersen Ro Source Type: research

Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease 　- Insights From the REAL-CAD Study
CONCLUSIONS: High-dose pitavastatin therapy compared with low-dose pitavastatin therapy was associated with a trend toward lowering the risk for cardiovascular events irrespective of the thrombotic risk in patients with CCS.PMID:35934778 | DOI:10.1253/circj.CJ-22-0315
Source: Circulation Journal - August 7, 2022 Category: Cardiology Authors: Masahiro Natsuaki Takeshi Morimoto Satoshi Iimuro Retsu Fujita Hiroshi Iwata Katsumi Miyauchi Teruo Inoue Yoshihisa Nakagawa Yosuke Nishihata Hiroyuki Daida Yukio Ozaki Satoru Suwa Ichiro Sakuma Yutaka Furukawa Hiroki Shiomi Hirotoshi Watanabe Kyohei Yama Source Type: research